Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To demonstrate an improvement in Progression-Free Survival (PFS) for Ombrabulin versus
placebo in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with
paclitaxel and carboplatin.
Secondary Objectives:
- To compare the overall survival (OS) between the 2 treatment arms
- To compare the objective response rate (RR) between the 2 treatment arms